Trevi Therapeutics, Inc. (TRVI) News
Track canonical SquawkNews coverage tagged to TRVI, Trevi Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 7 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
TRVI - Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 - Click For Relea
TRVI - Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
EARNINGS | Jul 30, 2026, 08:05 PM UTC
L
TRVI - Trevi Therapeutics to Participate in Upcoming August Conferences
TRVI - Trevi Therapeutics to Participate in Upcoming August Conferences
EQUITY | Jul 28, 2026, 11:30 AM UTC
L
TRVI new Outperform W/ $36 PT @ BMO
TRVI new Outperform W/ $36 PT @ BMO
EQUITY | Jul 21, 2026, 11:15 AM UTC
L
TRVI lows -11%
TRVI lows -11%
EQUITY | Jul 20, 2026, 07:42 PM UTC
L
TRVI View GSK's decision to halt camlipixant in RCC as a positive for TRVI, ending the P2X3 class and leaving Haduvio the leading differenti
TRVI View GSK's decision to halt camlipixant in RCC as a positive for TRVI, ending the P2X3 class and leaving Haduvio the leading differentiated candidate; Briley reiterate Buy and raise PT to $31 from $21 @ Briley
EQUITY | Jul 20, 2026, 01:09 PM UTC
H
ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday
U.S. stocks were lower, with the Nasdaq Composite falling around 400 points on Friday. Shares of ManpowerGroup Inc (NYSE: MAN ) rose sharply after the company reported upbeat second-quarter results and issued third-quart
EARNINGS | Jul 17, 2026, 02:09 PM UTC
L
TRVI highs up around 12%, benefiting from GSK stopping its Chronic cough study
TRVI highs up around 12%, benefiting from GSK stopping its Chronic cough study
EQUITY | Jul 17, 2026, 02:08 PM UTC